BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy


Por: M. SANCHO and M. ORZAEZ

Publicada: 2 ene 2021 Ahead of Print: 1 ene 2021
Resumen:
Myeloid cell leukemia 1 (MCL1) gene amplification occurs in a wide range of human cancers and protein overexpression associates with malignant cell growth and evasion of apoptosis. We recently reported that disrupting the interaction between the transmembrane domains of MCL1 and BCL-2 related ovarian killer (BOK) induces cell death, thereby suggesting a new target site for anti-tumorigenic strategies.

Filiaciones:
:
 Ctr Invest Principe Felipe, Lab Peptidos & Prot, Valencia 46012, Spain

:
 Ctr Invest Principe Felipe, Lab Peptidos & Prot, Valencia 46012, Spain
ISSN: 23723556





Molecular & Cellular Oncology
Editorial
TAYLOR & FRANCIS INC, 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106, Reino Unido
Tipo de documento: Editorial Material
Volumen: 8 Número: 1
Páginas: 1859918-1859918
WOS Id: 000607209000001
ID de PubMed: 33553610
imagen Green Published, Bronze

MÉTRICAS